StreetInsider.com News Articles

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Wed, 29 Jul 2026 08:05:00 -0400

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present at Canaccord Genuity’s 46th Annual Growth Conference, taking place August 11-13, 2026, in Boston, MA.

Presentation Details:
Date: Wednesday, August 12, 2026
Time: 12 PM EDT
Webcast Link: Canaccord Genuity / Candel Presentation

A webcast of the presentation will be available by selecting Events and Presentations in the Investors section

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Wed, 29 Jul 2026 08:05:00 -0400

Presentation Details:
Date: Wednesday, August 12, 2026
Time: 12 PM EDT
Webcast Link: Canaccord Genuity / Candel Presentation

A webcast of the presentation will be available by selecting Events and Presentations in the Investors section

H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Wed, 29 Jul 2026 06:52:36 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $23.00 price target on Candel Therapeutics Inc. (NASDAQ: CADL).

The analyst commented: "Our latest KOL research zeroed in on the question that may ultimately decide the commercial trajectory of aglatimagene besadenovec (CAN-2409): if approved, what will it take to move the therapy from regulatory clearance into prostate cancer guidelines and routine practice? To probe this, we interviewed three prostate cancer experts (omitting medical oncologists of course), each with direct experience serving on the AUA, ASTRO, or NCCN guideline committees and who were well versed in the aglatimagene profile. We steered the

Form SCHEDULE 13G Candel Therapeutics, Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260727/26820032.html

Form SCHEDULE 13G Candel Therapeutics, Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260727/26820032.html

Stifel Starts Candel Therapeutics Inc. (CADL) at Buy

Mon, 13 Jul 2026 02:13:19 -0400

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target of $22.00.

The analyst comments: “Aglatimagene is a differentiated/versatile, locally-administered viral immunotherapy with a dual mechanismof-action (directly cytotoxic and yielding systemic immune activation) which has been clinically-validated in multiple solid tumor settings. We believe registrational P3 PrTK03 trial data clearly establishes the superiority of aglatimagene (+valacyclovir) vs. placebo on a backbone of standard-of-care radiotherapy (± short-term ADT) in intermediate-risk localized prostate cancer (LPCa) patients, and remain confident a planned YE26 BLA submission will yield a 2H27 regulatory approval and commercial launch

Stifel Starts Candel Therapeutics Inc. (CADL) at Buy

Mon, 13 Jul 2026 02:13:19 -0400

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target of $22.00.

Form 4 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26747673.html

Form 4 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26747673.html

Form 3 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260708/26747657.html

Form 3 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260708/26747657.html

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 08 Jul 2026 16:05:00 -0400

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 2026, the Compensation Committee of Candel’s Board of Directors granted Mark Sims, in connection with his employment as the Chief Commercial Officer of Candel, stock options to purchase an aggregate of 285,000 shares of the Company’s common stock, with a per share exercise price of $10.03, which is equal to the closing price of the Company’s common

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 08 Jul 2026 16:05:00 -0400

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Barone Francesca

Wed, 01 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260701/26721055.html

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Barone Francesca

Wed, 01 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260701/26721055.html

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Tyagarajan Seshu

Wed, 01 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260701/26721042.html

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Tyagarajan Seshu

Wed, 01 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260701/26721042.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: PAPA JOSEPH C

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721009.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: PAPA JOSEPH C

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721009.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Manning Paul B

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721022.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Manning Paul B

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721022.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Loggia Nicoletta

Wed, 01 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26720996.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Loggia Nicoletta

Wed, 01 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26720996.html

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:05:00 -0400

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on June 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 25,000 shares of the Company’s common stock, with a per share exercise price of $10.30.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:05:00 -0400

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest